Global evaluation of echocardiography in patients with COVID-19

Marc R Dweck, Anda Bularga, Rebecca T Hahn, Rong Bing, Kuan Ken Lee, Andrew R Chapman, Audrey White, Giovanni Di Salvo, Leyla Elif Sade, Keith Pearce, David E Newby, Bogdan A Popescu, Erwan Donal, Bernard Cosyns, Thor Edvardsen, Nicholas L Mills, Kristina Haugaa, Marc R Dweck, Anda Bularga, Rebecca T Hahn, Rong Bing, Kuan Ken Lee, Andrew R Chapman, Audrey White, Giovanni Di Salvo, Leyla Elif Sade, Keith Pearce, David E Newby, Bogdan A Popescu, Erwan Donal, Bernard Cosyns, Thor Edvardsen, Nicholas L Mills, Kristina Haugaa

Abstract

Aims: To describe the cardiac abnormalities in patients with COVID-19 and identify the characteristics of patients who would benefit most from echocardiography.

Methods and results: In a prospective international survey, we captured echocardiography findings in patients with presumed or confirmed COVID-19 between 3 and 20 April 2020. Patient characteristics, indications, findings, and impact of echocardiography on management were recorded. Multivariable logistic regression identified predictors of echocardiographic abnormalities. A total of 1216 patients [62 (52-71) years, 70% male] from 69 countries across six continents were included. Overall, 667 (55%) patients had an abnormal echocardiogram. Left and right ventricular abnormalities were reported in 479 (39%) and 397 (33%) patients, respectively, with evidence of new myocardial infarction in 36 (3%), myocarditis in 35 (3%), and takotsubo cardiomyopathy in 19 (2%). Severe cardiac disease (severe ventricular dysfunction or tamponade) was observed in 182 (15%) patients. In those without pre-existing cardiac disease (n = 901), the echocardiogram was abnormal in 46%, and 13% had severe disease. Independent predictors of left and right ventricular abnormalities were distinct, including elevated natriuretic peptides [adjusted odds ratio (OR) 2.96, 95% confidence interval (CI) 1.75-5.05) and cardiac troponin (OR 1.69, 95% CI 1.13-2.53) for the former, and severity of COVID-19 symptoms (OR 3.19, 95% CI 1.73-6.10) for the latter. Echocardiography changed management in 33% of patients.

Conclusion: In this global survey, cardiac abnormalities were observed in half of all COVID-19 patients undergoing echocardiography. Abnormalities were often unheralded or severe, and imaging changed management in one-third of patients.

Keywords: COVID-19; Echocardiography.

© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.

Figures

Figure 1
Figure 1
Prevalence of COVID-19 and countries contributing to the global online survey of echocardiography. (A) The prevalence of COVID-19 on 20 April for the 185 countries for which data were available through the Johns Hopkins Center for Systems Science and Engineering COVID-19 dashboard. (B) The location and number of scans reported in the global online survey of echocardiography during a 17-day period from 3 to 20 April 2020.
Figure 2
Figure 2
Central Illustration. Mosaic plot illustrating the findings on echocardiography in patients with COVID-19. Mosaic plot illustrating the distribution of normal and abnormal echocardiogram findings in patients with suspected or confirmed COVID-19 infection. Box size is proportional to the number of patients per category. Left ventricular abnormalities are shown in orange and right ventricular abnormalities are shown in blue, both in the independent boxes and in the biventricular failure box. Survey respondents could enter data for multiple categories of left or right ventricular abnormality, therefore subcategories are not mutually exclusive. Eleven patients had evidence of cardiac tamponade which was an isolated finding in three patients, illustrated in purple. LV, left ventricle; MI, myocardial infarction; PAP, pulmonary arterial pressure.
Figure 3
Figure 3
Alluvial plot illustrating the indications for echocardiography and impact on patient management grouped according to the scan findings. Colours represent findings reported on echocardiography. All patients for whom complete data were available for indication, findings, and change in management were included in this plot [89% (1080/1216)]. The elevated biomarker indication subgroup includes both indication for raised troponin and indication for elevated BNP. Changes in management (impact) include those where changes in disease-specific therapy, titration of haemodynamic support, or changes in the level of patient care were described.
Figure 4
Figure 4
Predictors of an abnormal left (red) and right (blue) ventricle on echocardiography in patients with COVID-19 without pre-existing cardiac disease. Two multivariable logistic regression models examined the associations of clinical covariates with abnormal left ventricular or abnormal right ventricular findings on echocardiography. Categorical covariate data comprised only those answers that were pre-defined in survey questions and were selected a priori based on clinical relevance. *Those with mild symptoms were the referent group for symptom severity. BNP, brain type natriuretic peptide.

References

    1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS.. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708–1720.
    1. Gates B. Responding to Covid-19 – a once-in-a-century pandemic? N Engl J Med 2020;382:1677–1679.
    1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B.. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.
    1. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, Bi Z, Zhao Y.. Prevalence and impact of cardiovascular metabolic disease on COVID-19 in China. Clin Res Cardiol 2020;109:531–538.
    1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B.. Clinical course and risk factor for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–1062.
    1. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q, Huang H, Yang B, Huang C.. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol 2020:doi: 10.1001/jamacardio.2020.0950.
    1. Bangalore S, Sharma MHA, Slotwiner A, Yatskar L, Harari R, Shah B, Ibrahim H, Friedman GH, Thompson C, Alviar CL, Chadow HL, Fishman GI, Reynolds HR, Keller N, Hochman JS.. ST-segment elevation in patients with Covid-19 – a case series. N Engl J Med 2020;doi: 10.1056/NEJMc2009020.
    1. Hu H, Ma F, Wei X, Fang Y.. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J 2020;doi: 10.1093/eurheartj/ehaa190.
    1. Meyer P, Degrauwe S, Delden CV, Ghadri JR, Templin C.. Typical takotsubo syndrome triggered by SARS-CoV-2 infection. Eur Heart J 2020;41:1860.
    1. Chapman AR, Bularga A, Mills NL.. High-sensitivity cardiac troponin can be an ally in the fight against COVID-19. Circulation 2020;141:1733–1735.
    1. Tavazzi G, Pellegrini C, Maurelli M, Belliato M, Sciutti F, Bottazzi A, Sepe PA, Resasco T, Camporotondo R, Bruno R, Baldanti F, Paolucci S, Pelenghi S, Iotti GA, Mojoli F, Arbustini E.. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail 2020;22:911–915.
    1. Varga S, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H.. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020;395:1417–1418.
    1. Haugaa KH, Marsan NA, Cameli M, D’Andrea A, Dweck MR, Carvalho RF, Holte E, Manka R, Michalski B, Podlesnikar T, Popescu BA, Schulz-Menger J, Sitges M, Stankovic I, Maurer G, Edvardsen T.. Criteria for surveys: from the European Association of Cardiovascular Imaging Scientific Initiatives Committee. Eur Heart J Cardiovasc Imaging 2019;20:963–936.
    1. Cameli M, Marsan NA, D’Andrea A, Dweck MR, Fontes-Carvalho R, Manka R, Michalski B, Podlesnikar T, Sitges M, Popescu BA, Edvardsen T, Fox KF, Haugaa KH.. EACVI survey on multimodality training in ESC countries. Eur Heart J Cardiovasc Imaging 2019;20:1332–1336.
    1. Michalski B, Dweck MR, Marsan NA, Cameli M, D’Andrea A, Carvalho RF, Holte E, Robert TP, Haugaa KH.. The evaluation of aortic stenosis, how the new guidelines are implemented across Europe: a survey by EACVI. Eur Heart J Cardiovasc Imaging 2020;21:357–362.
    1. Madjid M, Miller CC, Zarubaev VV, Marinich IG, Kiselev OI, Lobzin YV, Filippov AE, Casscells SW 3rd. Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34 892 subjects. Eur Heart J 2007;28:1205–1210.
    1. Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, Katz K, Ko DT, McGeer AJ, McNally D, Richardson DC, Rosella LC, Simor A, Smieja M, Zahariadis G, Gubbay JB.. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med 2018;378:345–353.
    1. Vardeny O, Solomon SD.. Influenza vaccination: a one-shot deal to reduce cardiovascular events. Eur Heart J 2017;38:334–337.
    1. Madjid M, Connolly AT, Nabutovsky Y, Safavi-Naeini P, Razavi M, Miller CC.. Effect of high influenza activity on risk of ventricular arrhythmias requiring therapy in patients with implantable cardiac defibrillators and cardiac resynchronization therapy defibrillators. Am J Cardiol 2019;124:44–50.
    1. Cui S, Chen S, Li X, Liu S, Wang F.. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 2020;doi: 10.1111/jth.14830.
    1. Singh K, Mayo P.. Critical care echocardiography and outcomes in the critically ill. Curr Opin Crit Care 2018;24:316–321.
    1. Bethge A, Penciu O, Baksh S, Parve S, Lobraico J, Keller AM.. Appropriateness versus value: echocardiography in primary care. Clin Cardiol 2017;40:1212–1217.
    1. Skulstad H, Cosyns B, Popescu BA, Galderisi M, Salvo GD, Donal E, Petersen S, Gimelli A, Haugaa KH, Muraru D, Almeida AG, Schulz-Menger J, Dweck MR, Pontone G, Sade LE, Gerber B, Maurovich-Horvat P, Bharucha T, Cameli M, Magne J, Westwood M, Maurer G, Edvardsen T.. COVID-19 pandemic and cardiac imaging: EACVI recommendations on precautions, indications, prioritization, and protection for patients and healthcare personnel. Eur Heart J Cardiovasc Imaging 2020;21:592–598.
    1. Linschoten M, Asselbergs FW on behalf of CAPACITY-COVID collaborative consortium. CAPACITY-COVID: a European registry to determine the role of cardiovascular disease in the COVID-19 pandemic. Eur Heart J 2020;41:1795–796.
    1. Dong E, Du H, Gardner L.. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 2020;20:533–534.

Source: PubMed

3
Prenumerera